Mature T and NK Neoplasms (MSK, Blood Adv 2023)
Overview
Retrospective MSK cohort of adults with nodal peripheral T-cell lymphoma treated with curative-intent CHOP-based chemotherapy, profiled with MSK-IMPACT to identify somatic predictors of outcome PMID:37078708.
Composition
- 132 adults with nodal PTCL (PTCL-NOS, AITL, PTCL-TFH, ALK± ALCL) plus EATL and MEITL, treated at MSK 2015–2020 PMID:37078708.
- Histology mix: AITL 47%, PTCL-NOS 27%, ALK− ALCL 11%, PTCL-TFH 7%, ALK+ ALCL 5%, MEITL 3%; nested cohorts for complete clinical data (n=87) and prospective analysis (n=72) PMID:37078708.
Assays / panels (linked)
- MSK-IMPACT across IMPACT341 / IMPACT410 / IMPACT468 versions depending on era PMID:37078708.
Papers using this cohort
- PMID:37078708 — Johnson et al., TP53 mutations identify high-risk events for PTCL treated with CHOP-based chemotherapy.
Notable findings derived from this cohort
- Most frequently mutated genes: TET2 52%, RHOA 30%, DNMT3A 19%, TP53 16%, IDH2 11%; in AITL, 88% of RHOA mutations were canonical G17V PMID:37078708.
- TP53 mutations (HR 3.1; 95% CI 1.4–6.8; P=.005) and TP53/17p deletions (HR 4.1; 95% CI 1.1–15.0; P=.03) were the only somatic aberrancies correlating with inferior PFS; median PFS 4.5 vs 10.5 months (TP53-mut vs TP53-wt) PMID:37078708.
- CDKN2A deletions (n=9) correlated with inferior OS (HR 12.1; 95% CI 2.8–52.0; P<.001); 3/4 MEITL cases carried CDKN2A aberrancies PMID:37078708.
Sources
- cBioPortal study
mtnn_msk_2022PMID:37078708.
This page was processed by crosslinker on 2026-04-10.